KCP
PHAT icon

Kera Capital Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Kera Capital Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.3K Buy
+5,000
New +$57.1K 0.01% 627

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Kera Capital Partners's PHAT Position: Q2 2026 in Review

Kera Capital Partners held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 26,826 shares worth $291K. The position accounts for 0.03% of the portfolio, ranked #499.

Kera Capital Partners first reported a position in PHAT in Q4 2024 and has held it in 7 quarters since. The position peaked at $354K in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Kera Capital Partners held 26,826 shares of Phathom Pharmaceuticals worth $291K as of Q2 2026.
  • Kera Capital Partners left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up 0.03% of Kera Capital Partners's portfolio in Q2 2026, its #499 holding.
  • Kera Capital Partners first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Kera Capital Partners's Phathom Pharmaceuticals position peaked at $354K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.